Enzon Pharmaceuticals Inc. (ENZN)

Oncology Corporate Profile

Stock Performance

0.5093
0.0077

HQ Location

20 Kingsbridge Road
Piscataway Township, NJ 8854

Company Description

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar¥Ô, DepoCyt¥Ô, Abelcet¥Ô and Adagen¥Ô.

Website: http://www.enzon.com

Brand Generic Indication
Oncaspar«• pegaspargaseOncaspar is indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with first line acute lymphoblastic leukemia and hypersensitivity to asparaginase.

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PEG-SN38 (EZN-2208)PEGylated cytotoxic1st line metastatic Colorectal cancerII
EZN-3042RNA antagonist (survivin antagonist)2nd line metastatic Acute Lymphocytic Leukemia (ALL)I
PEG-SN38 (EZN-2208)PEGylated cytotoxicVarious cancer typesI
Oncaspar_ / pegaspargasePEG-L-asparaginaseNon-Hodgkin's Lymphoma (NHL)I
Oncaspar_ / pegaspargasePEG-L-asparaginaseVarious cancer typesI

View additional information on product candidates here »

Source


http://www.enzon.com

Recent News Headlines

Enzon Pharma Cuts More Jobs, to Stop Drug Development

12/21/2012 10:19 am

(Reuters) Dec 20, 2012 - Enzon Pharmaceuticals Inc said it will suspend all clinical development activities, days after the cancer drug developer decided to explore a possible sale.

Enzon Pharma Cuts More Jobs, to Stop Drug Development

12/21/2012 10:01 am

(Reuters) Dec 20, 2012 - Enzon Pharmaceuticals Inc said it will suspend all clinical development activities, days after the cancer drug developer decided to explore a possible sale.

Enzon to Review Potential Sale After Icahn Wants Talk

12/17/2012 11:39 am

(Bloomberg) Dec 17, 2012 - Enzon Pharmaceuticals Inc., a developer of cancer treatments, said it’s considering selling all or part of the business after billionaire investor Carl Icahn expressed interest in talking to the company.

Enzon to Review Potential Sale After Icahn Wants Talk

12/17/2012 11:03 am

(Bloomberg) Dec 17, 2012 - Enzon Pharmaceuticals Inc., a developer of cancer treatments, said it’s considering selling all or part of the business after billionaire investor Carl Icahn expressed interest in talking to the company.

Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference

6/19/2012 04:03 pm

[Marketwire] - PISCATAWAY, NJ-- - Enzon Pharmaceuticals, Inc. today announced the presentation of results from a Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors. ...

Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting

6/4/2012 06:01 pm

[Marketwire] - PISCATAWAY, NJ-- - Enzon Pharmaceuticals, Inc. today presented data from the final analysis of a Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic ...

Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China

5/7/2012 02:00 pm

[Marketwire] - PISCATAWAY, NJ and ZHEJIANG, CHINA-- - Enzon Pharmaceuticals, Inc. and Zhejiang Hisun Pharmaceuticals Co. Ltd , a leading Chinese pharmaceutical company, announced today a long-term strategic research, ...

Enzon Reports First Quarter 2012 Results

5/2/2012 12:00 pm

[Marketwire] - PISCATAWAY, NJ-- - Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2012. Enzon reported a net loss of $1.1 million, or $0.02 diluted loss per share, for the first ...

Enzon Reports Fourth-Quarter and Full-Year 2011 Results

3/12/2012 12:00 pm

[Marketwire] - PISCATAWAY, NJ-- - Enzon Pharmaceuticals, Inc. today announced its financial results for the fourth-quarter and full-year 2011. For the three months ended December 31, 2011, Enzon reported a loss from ...